HFNC Treatment in COVID-19 Pneumonia

NCT04424836 | Completed

• 1 other identifier: 5569
• Study Type: observational
• Target: 43
• Locations: 1 country
• Sites: 1

Brief Summary

coronavirus disease 2019 related pneumonia is causing acute respiratory failure and this is the most common reason for ICU admission. We have several different way for respiratory support. HFNC is one of the new technics for oxygen support. Our main purpose to observe the effect of HFNC on coronavirus disease 2019 patients' ICU stay and mortality.

Conditions

Coronavirus Infection; Pneumonia, Viral; Acute Respiratory Failure

Keywords

high flow nasal cannula (HFNC); conventional oxygen treatment (COT)

Outcome Measures

Primary Outcomes (2)

• short term mortality

  the mortality rate of patients

  in 28 days.

• icu stay

  means the stay day of patients in intensive care unit

  up to 28 days

Secondary Outcomes (1)

• blood gases

  at the admission time and 24th hour

Study Arms (2)

H GROUP

patients get the oxygen supply with high flow nasal cannula . In group H, HFNC device settings the initial flow rate was 30 L/min and could be increased to 60. The Fio2 was adjusted to maintain oxygen saturation as indicated by a pulse oximetry reading of grater than or equal to %90.

Device: high flow nasal cannula device

C GROUP

patients get the oxygen supply with conventional methods. In group C 6-15 L/min oxygen delivered to patients by conventional methods and targeted to maintain the oxygen saturation %90 or over.

Interventions

high flow nasal cannula device DEVICE

device is supplying oxygen with heated and humidified air in a high flow rate

H GROUP

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

coronavirus disease 2019 patients admitted to the ICU for acute respiratory failure 15 march to 15 may

You may qualify if:

• We include the patient with acute respiratory failure related coronavirus disease 2019 (diagnosed with polymerase Chain Reaction), older than 18 year and supported by High Flow Nasal cannulae or conventional oxygen treatment(COT).

You may not qualify if:

• Patients with primary pulmonary disease, Glasgow Coma scale≤ 12 , respiratory acidosis in the first blood gases(ph≤ 7,2 - pCO2≥50) will exclude.

Sponsors & Collaborators

• Sisli Hamidiye Etfal Training and Research Hospital: lead

Study Sites (1)

Sisli Etfal Research and Training Hospital

Istanbul, 34371, Turkey (Türkiye)

Location

Related Publications (3)

• Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A; COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394.

  PMID: 32250385 RESULT

• Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, Hawa H, Alothman A, Khaldi A, Al Raiy B. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014 Mar 18;160(6):389-97. doi: 10.7326/M13-2486.

  PMID: 24474051 RESULT

• Akerstrom S, Gunalan V, Keng CT, Tan YJ, Mirazimi A. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. Virology. 2009 Dec 5;395(1):1-9. doi: 10.1016/j.virol.2009.09.007. Epub 2009 Oct 1.

  PMID: 19800091 RESULT

MeSH Terms

Conditions

Coronavirus Infections; Pneumonia, Viral

Condition Hierarchy (Ancestors)

Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Pneumonia; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• ayse su cinar

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: specialist medical doctor

Study Record Dates

• First Submitted: June 7, 2020
• First Posted: June 11, 2020
• Study Start: May 15, 2020
• Primary Completion: June 4, 2020
• Study Completion: June 5, 2020
• Last Updated: July 16, 2020

Record last verified: 2020-07

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)